Biogen INC Form 4 insider transactions

Priya Singhal, Head of Development at Biogen, reported the acquisition of 1,828 shares of common stock through the vesting of restricted stock units and the disposal of 578 shares to cover tax obligations.

Biogen's Head of Development, Priya Singhal, reported multiple transactions involving company stock, including the vesting of restricted stock units and subsequent sales.

Biogen's Chief Accounting Officer, Robin Kramer, reports the acquisition of 351 shares and the disposal of 170 shares of common stock on December 6, 2024.

EVP and Chief Legal Officer of Biogen, Susan Alexander, reports gifting shares to an irrevocable trust for her children.

Jane Grogan, Head of Research at Biogen, reports the acquisition and disposal of common stock and restricted stock units on November 1, 2024.

Priya Singhal, Head of Development at Biogen, reports the acquisition and disposal of Biogen common stock and restricted stock units.

Director Stephen Sherwin reported the acquisition and disposal of Biogen (BIIB) common stock on June 21, 2024.

Director Jesus B. Mantas reports changes in beneficial ownership of Biogen Inc. common stock, including acquisition and disposal of shares on June 21, 2024.

Director Eric K. Rowinsky reports changes in beneficial ownership of Biogen Inc. stock, including the acquisition of 1,340 shares.

Director Susan Langer reported acquiring 1,340 shares of Biogen Inc. common stock on June 21, 2024.

Director Monish D Patolawala acquired 1,340 shares of Biogen Inc. common stock on June 21, 2024.

Director William Hawkins of Biogen Inc. reports acquisition and disposal of common stock on June 21, 2024.

Director Maria C Freire reports acquiring 1,340 shares of Biogen stock and disposing of 4,445 shares on June 21, 2024.

Director Caroline Dorsa reported acquiring 1,785 shares of Biogen Inc. common stock on June 21, 2024.

Adam Keeney, Head of Corporate Development at Biogen, reports the vesting and subsequent disposal of restricted stock units.

Priya Singhal, Head of Development at Biogen Inc., reported the sale of 93 shares of common stock on April 2, 2024.

Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, reports the acquisition and disposal of company stock and restricted stock units on April 1, 2024.